6/1/09 - 5/31/14
Jesse Dallery, PhD
Other Project Staff
Bethany Raiff, PhD; Lisa A. Marsch, PhD; Maxine Stitzer; Mike Grabinski
Cigarette smoking is the largest preventable risk factor for morbidity and mortality in developed countries. Although the United States Public Health Service endorses various pharmacotherapies and counseling for smoking cessation, the majority of patients relapse within six months, even when both treatments are used together. The limitations of current interventions highlight the urgent need for innovative, powerful, and community-friendly treatments. Abstinence reinforcement therapy is one such treatment.
We developed and tested an internet-based monitoring system to verify and reinforce smoking abstinence by breath carbon monoxide (CO) output. By using this simple yet innovative method, we found that patients were highly engaged with the treatment, and that voucher reinforcement produced high rates of sustained abstinence in a group of heavy smokers (over 65% of the 400 CO samples were negative during treatment). In the proposed project, we will evaluate a broadly applicable, sustainable, and clinically feasible abstinence reinforcement intervention. The treatment delivery model integrates the reach and convenience of the internet with a state-of-the-art, empirically-derived behavioral treatment for cigarette smoking. Smokers will be randomly assigned to an abstinence reinforcement group or to a control group, and smoking status will be measured during treatment and at a 6-month follow-up. Treatment can continue uninterrupted during the initial weeks of a quit attempt, which growing evidence suggests is a critical period to promote long-term cessation.
To complement our individualized user-friendly CO measurement technology and make the treatment even more personally salient to participants, we will incorporate a deposit contract procedure. Participants will contribute a specified amount of money that they can recoup based on evidence of abstinence. This method holds promise as a way to substantially offset the costs associated with treatment. Finally, we will employ a remote treatment delivery model such that distance will not be a barrier. The treatment can be disseminated to any qualified smoker in the United States.
The proposed program is innovative and directly addresses some of the major limitations (cost, sustainability, access) inherent in traditional abstinence reinforcement delivery models, and it has the potential to be appealing and feasible for widespread dissemination. If the promise of the intervention is realized, it will reduce the high rates of morbidity and mortality associated with smoking.
Public Health Relevance
Cigarette smoking is the largest preventable risk factor for morbidity and mortality in the United States. The proposed treatment will integrate the reach and convenience of the internet with a state-of-the-art, empirically-derived behavioral treatment for cigarette smoking: abstinence reinforcement therapy. The current program is innovative and directly addresses some of the major limitations (cost, sustainability, dissemination) inherent in traditional abstinence reinforcement delivery models. The intervention has the potential to be appealing and feasible for widespread dissemination. As such, this technological innovation in a behavioral treatment for cigarette smoking holds significant promise as a way to reduce the high rates of morbidity and mortality associated with smoking.
Note: A family member of CTBH’s Director, Dr. Marsch, developed and licenses Motiv8. This relationship is managed by her academic institution.